2-Phenyl-3-(piperazin-1-ylmethyl)imidazo[1,2-a]pyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-Phenyl-3-(piperazin-1-ylmethyl)imidazo[1,2-a]pyridine
• 化学式: C₁₈H₂₀N₄
• 分子量: 292.4
• InChiKey: XIKCPUYIKHDSKZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  32.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• SUBSTITUTED PERHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AND THE USE OF SAME
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20180370965A1

  公开（公告）日：2018-12-27

  The present application relates to novel (2-phenylimidazo[1,2-a]pyridin-3-yl)methyl-substituted perhydropyrrolo[3,4-c]pyrrole derivatives, to methods for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of respiratory disorders including sleep-related respiratory disorders such as obstructive sleep apneas and central sleep apneas and snoring.

  本申请涉及新颖的(2-苯基咪唑[1,2-a]吡啶-3-基)甲基取代的过氢吡咯[3,4-c]吡咯衍生物，其制备方法，单独或组合使用以治疗和/或预防疾病，以及用于生产用于治疗和/或预防疾病的药物，特别是用于治疗和/或预防呼吸系统疾病，包括与睡眠有关的呼吸系统疾病，如阻塞性睡眠呼吸暂停症、中枢性睡眠呼吸暂停症和打鼾。
• SUBSTITUTED DIAZAHETERO-BICYCLIC COMPOUNDS AND THEIR USE
  申请人：Bayer Aktiengesellschaft

  公开号：US20210024545A1

  公开（公告）日：2021-01-28

  The present application relates to novel (imidazo[1,2-a]pyridin-3-yl)methyl-substituted diazaheterobicyclic compounds, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of respiratory disorders including sleep-related respiratory disorders such as obstructive sleep apnoea and central sleep apnoea and snoring. The present application further relates to a method of discovering a compound having TASK-1-and/or TASK-3-blocking properties.

  本申请涉及新颖的（咪唑[1,2-a]吡啶-3-基）甲基取代的二氮杂杂双环化合物，其制备方法，单独或组合使用以治疗和/或预防疾病，以及用于生产用于治疗和/或预防疾病的药物的用途，特别是用于治疗和/或预防呼吸系统疾病，包括睡眠相关的呼吸系统疾病，如阻塞性睡眠呼吸暂停症、中枢性睡眠呼吸暂停症和打鼾。本申请还涉及一种发现具有TASK-1和/或TASK-3阻断特性的化合物的方法。
• Substituted perhydropyrrolo[3,4-c]pyrrole derivatives and the use of same
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US10414765B2

  公开（公告）日：2019-09-17

  The present application relates to novel (2-phenylimidazo[1,2-a]pyridin-3-yl)methyl-substituted perhydropyrrolo[3,4-c]pyrrole derivatives, to methods for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of respiratory disorders including sleep-related respiratory disorders such as obstructive sleep apneas and central sleep apneas and snoring.

  本申请涉及新型(2-苯基咪唑并[1,2-a]吡啶-3-基)甲基取代的全氢吡咯并[3,4-c]吡咯衍生物、其制备方法、其单独使用或组合使用以治疗和/或预防疾病，以及其用于生产治疗和/或预防疾病的药物，特别是用于治疗和/或预防呼吸系统疾病，包括与睡眠有关的呼吸系统疾病，如阻塞性睡眠呼吸暂停和中枢性睡眠呼吸暂停以及打鼾。
• 2-phenyl-3-(piperazinomethyl)imidazo[1,2-A]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US10759794B2

  公开（公告）日：2020-09-01

  The present application relates to novel 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridine derivatives, to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases, and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for treatment and/or prevention of respiratory disorders including, sleep-related respiratory disorders such as obstructive sleep apnoeas and central sleep apnoeas and snoring.

  本申请涉及新型 2-苯基-3-(哌嗪甲基)咪唑并[1,2-a]吡啶衍生物、其制备工艺、其单独使用或组合使用以治疗和/或预防疾病，以及其用于制备治疗和/或预防疾病的药物，特别是用于治疗和/或预防呼吸系统疾病，包括与睡眠相关的呼吸系统疾病，如阻塞性睡眠呼吸暂停、中枢性睡眠呼吸暂停和打鼾。
• 2-PHENYL-3-(PIPERAZINOMETHYL)IMIDAZO[1,2-A]PYRIDIN-DERIVATE ALS BLOCKER DER TASK-1 UND TASK-2 KANÄLE ZUR BEHANDLUNG VON SCHLAFBEDINGTEN ATEMSTÖRUNGEN
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：EP3386979A1

  公开（公告）日：2018-10-17